EX-99.1 2 v377259_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1  

 

Medifast Logo295

 

Medifast, Inc. Announces First Quarter 2014 Financial Results

 

Company Exceeds Earnings per Share Guidance; First Quarter Earnings per Diluted Share Increases to $0.45

 

OWINGS MILLS, Md., May 5, 2014 – Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, today reported financial results for the first quarter ended March 31, 2014.

 

“Our ongoing efforts to execute on our strategic goals enabled us to generate earnings results ahead of our expectations for the first quarter,” said Michael C. MacDonald, Medifast’s Chairman and Chief Executive Officer. “I am extremely pleased with our team’s ability to carefully manage the controllable aspects of our business which helped us achieve a 110 basis point improvement in operating margin. We believe our first quarter financial results are a positive start to what we expect will be another solid year for Medifast.”

 

First Quarter 2014 Results 

 

Operating income was $8.7 million, or 10.0% as a percent of net revenue, compared to $8.6 million or 8.9% as a percent of net revenue in the first quarter of 2013.

 

Net income was $6.0 million, or $0.45 per diluted share compared to net income of $5.9 million, or $0.43 per diluted share for the first quarter of 2013.

 

For the first quarter ended March 31, 2014, Medifast net revenue decreased 10% to $86.5 million from net revenue of $96.0 million in the first quarter of the prior year.  Revenue in the direct sales channel, Take Shape for Life, decreased 4% to $57.0 million in the first quarter of 2014 compared to $59.4 million in the same period last year. The decrease in revenue for Take Shape for Life was driven by a slight decrease in the number of health coaches and revenue per health coach. The Company ended the first quarter with approximately 11,100 active health coaches and the average revenue per health coach per month for the quarter decreased to $1,626 compared to $1,720 in the first quarter of 2013.

 

Sales and marketing expense decreased by $3.2 million in the first quarter of 2014 compared to first quarter of 2014. This decrease is the result of lower advertising spending in the first quarter of 2014 as compared to the first quarter of 2013. In the first quarter of 2014, the Company’s revenue to spend ratio was 12.5-to-1 versus 9.6-to-1 in the first quarter of 2013. The Company continues to focus on efficiency improvements and balancing sales and marketing expense in an effort to drive profitability.

 

 
 

 

The Company's Medifast Direct channel revenue decreased 26% to $17.1 million, compared to $23.0 million in the first quarter of 2013.  The decrease in revenue in this channel was primarily due to a reduction in sales and marketing spend as the Company continues to monitor consumer spending patterns. Spending efficiency in the quarter was strong and the Company will begin to invest additional dollars into marketing throughout the remainder of the year while continuing to focus on efficient management of those investments.

 

In the first quarter, the Medifast Weight Control Centers and Wholesale Physicians channel revenue decreased 9% to $12.4 million, compared to $13.6 million in the same period last year. The Company remained focused on profitability improvement by creating operational efficiencies, optimizing staffing levels, and managing expenses. As of March 31, 2014 Medifast had 75 corporate-owned and 49 franchise centers.  Going forward, the Company will continue to expand the number of franchise locations as corporate centers are also transitioned to the franchise model.

 

Gross profit for the first quarter of 2014 decreased 12% to $63.9 million, compared to $72.4 million in the first quarter of the prior year. The Company's gross profit margin decreased 150 basis points to 73.9% in the first quarter versus 75.4% in the first quarter of 2013. The decrease in gross profit margin during the quarter was the result of increased shipping and manufacturing costs, lower sales volume in the Company’s higher margin Medifast Direct Sales channel and reduced program sales.

 

Selling, general and administrative expenses decreased $8.6 million to $55.2 million compared to $63.8 million in the first quarter of 2013. As a percentage of revenue, selling, general and administrative expenses decreased 270 basis points to 63.8% versus 66.5% in the first quarter of 2013.

 

The Company had an effective tax rate of 33.7% compared to 31.9% in the first quarter of 2013. The prior year tax rate was positively impacted by research and development credits which were retroactive to 2012.

 

Balance Sheet 

 

The Company's balance sheet remains strong with stockholders' equity of $105.2 million and working capital of approximately $72.8 million as of March 31, 2014.  Cash, cash equivalents, and investment securities for the first quarter of 2014 increased $9.6 million to $77.4 million compared to $67.8 million at December 31, 2013. As previously announced, the Company paid off the remaining value of its outstanding long term notes and remains free of interest bearing debt.

 

 
 

 

Outlook

 

The Company expects second quarter 2014 net revenue to be in the range of approximately $85 to $88 million. Earnings per diluted share are expected to be in the range of $0.37 to $0.40 based on a 34% effective tax rate. For fiscal year 2014, the Company reiterated its previous guidance of net revenue to be in the range of $340 to $380 million and earnings per diluted share in the range of $1.80 to $1.90.  The Company anticipates a full year tax rate of approximately 33% to 34% in 2014.

 

Conference Call Information

 

The conference call is scheduled to begin at 4:30 p.m. ET on May 5, 2014. The call will be broadcast live over the Internet hosted at the Investor Relations section of Medifast's website at www.medifastnow.com, and will be archived online through May 19, 2014. In addition, listeners may dial (877) 705-6003.

 

A telephonic playback will be available from 7:30 p.m. ET, May 5, 2014, through May 19, 2014. Participants can dial (877) 870-5176 to hear the playback and enter passcode 13580710.

 

About Medifast

 

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. The company sells its products and programs via four unique distribution channels: 1) the Web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto www.MedifastNow.com.

 

 
 

 

Forward Looking Statements

 

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Health Coaches and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

 

Investor Contact:

ICR, Inc.

Katie Turner

(646) 277-1228

 

MED-F

 

 
 

 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   (Unaudited)   (Audited) 
   March 31, 2014   December 31, 2013 
           
ASSETS          
Current assets:          
Cash and cash equivalents  $41,360,000   $36,382,000 
Accounts receivable-net of allowance for sales returns and doubtful accounts of $561,000 and $647,000   1,524,000    1,246,000 
Inventory   15,896,000    18,059,000 
Investment securities   36,000,000    31,420,000 
Prepaid expenses and other current assets   2,943,000    2,890,000 
Deferred tax assets   2,125,000    1,957,000 
Total current assets   99,848,000    91,954,000 
           
Property, plant and equipment - net   39,057,000    40,336,000 
Other assets   341,000    360,000 
           
TOTAL ASSETS  $139,246,000   $132,650,000 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable and accrued expenses  $26,159,000   $26,780,000 
Income taxes payable   709,000    99,000 
Current maturities of capital leases   224,000    222,000 
Total current liabilities   27,092,000    27,101,000 
           
Other liabilities:          
Capital leases, net of current portion   417,000    474,000 
Deferred tax liabilities   6,568,000    6,659,000 
Total liabilities   34,077,000    34,234,000 
           
Stockholders' Equity:          
Preferred stock, $.001 par value (1,500,000 authorized, no shares issued and outstanding)   -    - 
Common stock; par value $.001 per share; 20,000,000 shares authorized; 13,143,309 issued; 13,131,642 and 13,115,642 issued and outstanding   13,000    13,000 
Additional paid-in capital   774,000    - 
Accumulated other comprehensive income   715,000    703,000 
Retained earnings   103,667,000    97,700,000 
Total stockholders' equity   105,169,000    98,416,000 
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $139,246,000   $132,650,000 

 

 
 

 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

 

   Three Months Ended March 31, 
   2014   2013 
         
Revenue  $86,529,000   $96,043,000 
Cost of sales   22,595,000    23,634,000 
Gross Profit   63,934,000    72,409,000 
           
Selling, general, and administration   55,238,000    63,831,000 
           
Income from operations   8,696,000    8,578,000 
           
Other income          
Interest and dividend income, net   126,000    52,000 
Other income   184,000    80,000 
    310,000    132,000 
           
Income before income taxes   9,006,000    8,710,000 
Provision for income taxes   3,039,000    2,777,000 
           
Net income  $5,967,000   $5,933,000 
           
Basic earnings per share  $0.45   $0.43 
Diluted earnings per share  $0.45   $0.43 
           
Weighted average shares outstanding -          
Basic   13,160,294    13,809,130 
Diluted   13,248,156    13,913,343